Other

Beecham-Wuelfing Gmbh & Co. Kg

Beecham-Wulfing Gmbh & Co. Kg

Joachim E Goring

Manfred Tauscher

Karl Credner

Gunter Brenner

Gunther Brenner

Oskar Rohte

Eskendar Ali Khan

Peter P Ochlich

Brian Morgan

Jonathan R Arch

Charles D Nicholson

Dieter Angersbach

Wolfgang Busch

A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

Novel treatment

Compounds of the formula (II): ##STR1## wherein: X is sulphur and Y is oxygen or sulphur;

Xanthine derivatives and their use in pharmaceutical compositions

Ketals of 1-(1,3-dialkylxanthin-7-yl)propan-2-ones are of use in the treatment of vascular disorders. A representative embodiment is 2-methyl-2-(1,3-dibutylxanthin-7-ylmethyl)-1,3-dioxalane.

Xanthine derivatives, and their use in pharmaceutical compositions

Compounds of the formula (I): ##STR1## wherein R is C.sub.1-4 alkyl, pharmaceutical compositions containing them and a process for their preparation. The compounds are useful for the treatment of peripheral vascular diseases in mammals.

1-(5-Oxohexyl)-3-alkyl-7-(2-oxopropyl)xanthines

7-(Oxoalkyl)-1,3-dialkyl xanthines whose substituents in the 1- and 3-positions are alkyl groups of 2 to 6 carbons, cyclohexyl, alkoxyalkyl or hydroxyalkyl, such as 7-(3-oxobutyl)-1,3-di-n-butylxanthine, are effective vasodilators, having a marked activity in promoting blood flow through skeletal muscle, while at the same time exhibiting low toxicity.

7-(Oxoalkyl)-1,3-di-n-iso-propyl xanthines and their production

It has been found that 1,3-di-n-butyl-7-(2-oxopropyl)xanthine is a particularly effective agent for increasing oxygen partial pressure and contractility in ischaemic and skeletal muscle. Pharmaceutical compositions containing 1 to 30 mg of this agent are described.

Pharmaceutical compositions

7-(Oxoalkyl)-1,3-dialkyl xanthines, and medicaments containing them

Pharmaceutical composition containing a xanthine derivative

The salts of N-unsubstituted, N-monosubstituted and N,N-disubstituted 7-(3-amino-2-hydroxypropyl)theophylline and 5-methylisoxazole-3-carboxylic acid are hypolipidaemic agents. The compounds, of which the 7-[3-(N-methyl-N-2-hydroxyethyl)amino-2-hydroxypropyl]-theophylline salt of 5-methylisoxazole-3-carboxylic acid is a representative embodiment, are prepared by allowing the isoxazole acid and the amine to react.

Theophylline salts of 5-methylisoxazole-3-carboxylic acid

This invention relates to 3-methylpyrazole-5-carboxylates, to processes for the preparation of said compounds and to pharmaceutical compositions containing said compounds.

3-Methylpyrazole-5-carboxylates and medicaments containing these

1,3-BIS(.beta.-ETHYLHEXYL)-5-AMINO-5-METHYLHEXAHYDROPYRIMIDINE PYRIDINE-3-CARBOXYLATE(HEXETIDINE NICOTINATE), WHICH HAS GREATER BACTERIOSTATIC ACTIVITY AND LOWER TOXICITY IN COMPARISON WITH HEXETIDINE OR OTHER SALTS OF HEXETIDINE, IS PREPARED BY REACTING HEXETIDINE OR AN ACID ADDITION SALT THEREOF WITH NICOTINIC ACID IN AN ORGANIC SOLVENT.

Growing community of inventors

Gronau, Germany

Joachim E Goring